NCT02143713View on ClinicalTrials.gov

Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

May 27, 2014

Primary Completion Date

June 22, 2016

Study Completion Date

May 23, 2017

Conditions
Endometriosis
Interventions
DRUG

Elagolix

Elagolix tablets administered orally

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY